Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection

Infection ◽  
2018 ◽  
Vol 46 (6) ◽  
pp. 871-874 ◽  
Author(s):  
Lena M. Biehl ◽  
Rebeca Cruz Aguilar ◽  
Fedja Farowski ◽  
Werner Hahn ◽  
Angela Nowag ◽  
...  
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Transplant Recipient ◽  
Kidney Transplant ◽  
Recurrent Urinary Tract Infection ◽  
Fecal Microbiota Transplantation ◽  
Kidney Transplant Recipient ◽  
Fecal Microbiota

scholarly journals Fecal Microbiota Transplantation for the Treatment of Refractory Recurrent Urinary Tract Infection

2020 ◽  
Vol 136 (4) ◽  
pp. 771-773
Author(s):  
Sarah E. S. Jeney ◽  
Felicia Lane ◽  
Andrew Oliver ◽  
Katrine Whiteson ◽  
Sonia Dutta
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Recurrent Urinary Tract Infection ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota

scholarly journals Fecal Microbiota Transplantation and Urinary Tract Infection: An Interesting Approach

2017 ◽  
Vol 66 (3) ◽  
pp. 483-483 ◽  
Author(s):  
Benjamin Davido ◽  
Aurélien Dinh ◽  
Laurene Deconinck ◽  
Pierre de Truchis
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Interesting Approach

Methenamine for Recurrent Urinary Tract Infections in Solid Organ Transplantation

2021 ◽  
pp. 152692482110648
Author(s):  
Helen Sweiss ◽  
Suverta Bhayana ◽  
Reed Hall ◽  
Joelle Nelson ◽  
Elisabeth Kincaide
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Kidney Transplant ◽  
Urinary Tract Infections ◽  
Recurrent Urinary Tract Infection ◽  
Solid Organ ◽  
Therapy Initiation ◽  
Tract Infections

Introduction Recurrent urinary tract infections remain a challenge in solid organ transplant and have a negative impact on morbidity/mortality. Project Aim The purpose of this program evaluation was to determine the impact of methenamine on recurrent urinary tract infection in kidney and liver-kidney transplant recipients. Design This retrospective review included patients > 18 years of age who received a kidney or liver-kidney transplant. Patients were divided into the following groups: (1) Methenamine therapy initiation received methenamine for ≥ 180 days or (2) Non-methenamine therapy: did not receive recurrent urinary tract infection prophylaxis. A total of 60 patients were included. Results When comparing outcomes between methenamine therapy initiation and non-methenamine therapy group, a significant reduction in the rate of recurrent urinary tract infection was reported in the methenamine therapy initiation group (0.6 vs 1.3 per 180 patient days follow-up, P = 0.0005). A significant reduction was also noted with rate of asymptomatic bacteriuria, treatment failures, bacteremia, hospitalizations due to recurrent urinary tract infection, multi-drug resistant organism isolated, and the average duration of antibiotic use. A significant difference in the time to failure of methenamine therapy initiation versus non-methenamine therapy is noted up to 180 patient-days follow-up (RR 1.56, P = 0.0019). Conclusion This evaluation supported methenamine therapy for recurrent urinary tract infection in kidney and liver-kidney transplant. The most significant impact of methenamine recurrent urinary tract infection was seen in the first 30 days after initiation.

Risk Factors for Recurrent Urinary Tract Infection in Kidney Transplant Recipients

2012 ◽  
Vol 94 (10S) ◽  
pp. 870 ◽  
Author(s):  
G.-Y. Park ◽  
J.-H. Cho ◽  
J.-H. Lim ◽  
J.-S. Kim ◽  
Y.-J. Kang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Kidney Transplant ◽  
Recurrent Urinary Tract Infection ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document